SNORA12: A Potential Drug Target and Biomarker (G677800)

Target Name: SNORA12

NCBI ID: G677800

SNORA12

Other Name(s): small nucleolar RNA, H/ACA box 12 | U108 | Small nucleolar RNA, H/ACA box 12

SNORA12: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in regulating gene expression in eukaryotic cells. One of the most well-known snRNAs is H/ACA box 12 (SNORA12), which is expressed in high levels in various tissues and cell types. Although the primary function of SNORA12 is not well understood, several studies have suggested that it may be involved in various cellular processes, including DNA replication, gene regulation, and stress response. As a result, SNORA12 has generated a lot of interest as a potential drug target and biomarker.

The H/ACA box is a conserved region that is present in many snRNAs. It is located at the start of the coding sequence and is responsible for binding to the H/ACA protein, which is a key regulator of RNA stability and quality control. The H/ACA box is also known as the "switch domain" because it is involved in the regulation of gene expression. The presence or absence of specific snRNA species at the H/ACA box can affect the stability and translation efficiency of the corresponding mRNA.

SNORA12 is a 24-nt snRNA that is expressed in various tissues and cell types, including brain, heart, liver, and muscle. It is highly expressed in the brain, where it is a prominent player in the regulation of synaptic plasticity and learning. SNORA12 has also been shown to be involved in the regulation of stem cell proliferation and the development of various tissues, including neural stem cells and hematopoietic stem cells.

One of the most promising aspects of SNORA12 is its potential as a drug target. The H/ACA box is a known drug target for small molecules, and the presence of SNORA12 at this location suggests that it may be a good candidate for drug targeting. Additionally, the fact that SNORA12 is highly expressed in various tissues and cell types makes it an attractive biomarker for drug development.

Another potential mechanism by which SNORA12 may be involved in drug targeting is its role in cellular signaling pathways. The H/ACA box is known to be involved in various cellular signaling pathways, including the regulation of DNA replication and stress response. Therefore, drugs that can modulate the activity of SNORA12 may have potential therapeutic applications in diseases that are caused by disruptions in these signaling pathways, such as cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, SNORA12 is a well-known snRNA that is expressed in various tissues and cell types. Its function is not well understood, but several studies have suggested that it may be involved in various cellular processes, including DNA replication, gene regulation, and stress response. As a result, SNORA12 has generated a lot of interest as a potential drug target and biomarker. The H/ACA box is a known drug target for small molecules, and the presence of SNORA12 at this location suggests that it may be a good candidate for drug targeting. Additionally, the fact that SNORA12 is highly expressed in various tissues and cell types makes it an attractive biomarker for drug development. Further research is needed to fully understand the function of SNORA12 and its potential as a drug target and biomarker .

Protein Name: Small Nucleolar RNA, H/ACA Box 12

The "SNORA12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets